Jim Cramer Says “I Should Have Pulled the Trigger on Regeneron” [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) is one of the stocks Jim Cramer looked at . When a caller inquired about the stock, Cramer said: Oh man, you know what? I should have pulled the trigger on Regeneron when I sat down with them at the JPMorgan conference. I realized that the Charitable Trust should have owned it. It would've a much better, really much better drug stock than the others that we have, with the exception of Eli Lilly. Stock market data. Photo by Photo by Alesia Kozik Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) sells medicines for eye conditions, immune disorders, cancer, cardiovascular issues, infections, and rare diseases. During the December 1, 2025, episode, a caller highlighted that the stock is up significantly from its summer 2025 lows and asked Cramer if it can continue its momentum. In response, the Mad Money host stated: Yes, down 30 today… Well, it's a $750 stock. Now, let me just tell you something. Regeneron's move has been quiet, but Le
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- These 5 New York companies are among America's best employers [USA TODAY]USA TODAY
- Regeneron Pharmaceuticals (REGN) had its price target raised by Royal Bank Of Canada from $745.00 to $765.00. They now have a "sector perform" rating on the stock.MarketBeat
- Regeneron's Dupixent Win And Rare Disease Push Reshape Risk Reward Profile [Yahoo! Finance]Yahoo! Finance
- Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq? [Yahoo! Finance]Yahoo! Finance
- Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds [Yahoo! Finance]Yahoo! Finance
REGN
Earnings
- 1/30/26 - Beat
REGN
Sec Filings
- 3/3/26 - Form 4
- 2/23/26 - Form 4
- 2/19/26 - Form 144
- REGN's page on the SEC website